Brind.
  1. The FDA accepted the BLA submission for Tabelecleucel and granted Priority Review, with Pierre Fabre Pharmaceuticals Inc. preparing for approval.

Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.

1 report, 1 independent Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.

Who's involved

What this event is mainly about
Atara Biotherapeutics, Inc.

Keep exploring

Part of

The FDA accepted the BLA submission for Tabelecleucel and granted Priority Review, with Pierre Fabre Pharmaceuticals Inc. preparing for approval. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswirePerre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. Pierre Fabre Laboratories is now responsible for all gl